Handan Ankarali, Tuba Soysal, Fatih Ermis

α-Galactosidase levels in irritable bowel syndrome subtypes and quality of life of patients

Aim: There is a requirement for a reliable serologic marker that can be used for the diagnosis of Irritable Bowel Syndrome (IBS). The aim of our study was to research whether serum levels of Alpha-galactosidase (AG) is associated with IBS and to assess quality of life (QOL) of IBS patients. Materials and Methods: 110 adult patients who were diagnosed with IBS were evaluated. 90 patients and 25 healthy volunteers were included. Patients were classified into subtypes: IBS-Diarrhea (IBS-D), IBS-Constipation (IBS-C), IBS-Mixed (IBS-M), and 30 patients were enrolled for each group. We administered the Short Form 36 (SF-36) to participants to evaluate QOL. Serum AG levels of participants was determined. Results: The mean AG levels of IBS-C and control group were significantly lower than the other groups (p

PDF

___

1. Lacy, Brian E. Diagnosis and treatment of diarrheapredominant irritable bowel syndrome. Int J Gen Med 2016;9:7.
2. Basnayake, Chamara. Treatment of irritable bowel syndrome. Aust Prescr 2018;41:145.
3. Halland, Magnus; SAITO, Yuri A. Irritable bowel syndrome: new and emerging treatments. bmj, 2015; 350: h1622.
4. Di Stefano, Michele, et al. The effect of oral α-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci 2007;52:78-83.
5. Hıllılä, Markku, et al. Does oral α-galactosidase relieve irritable bowel symptoms?. Scand J Gastroenterol 2016;51:16-21.
6. Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:834-42.
7. Jennifer YL, Biniam K, Farouq M, Brian MT,et al. Improved health-related quality of life after surgical management of severe refractory constipationdominant irritable bowel syndrome. Int Surg 2015;100:63-9.
8. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? : a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010;105:848-58.
9. Sood R, Gracie DJ, Law GR, et al. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015;42:491-503.
10. Ruchit S, Alexander C Ford. Combining biomarkers in irritable bowel syndrome: a forward step toward making a positive diagnosis and directing therapy? Gastroenterology 2015;148:1471-3.
11. Mujagic Z, Tigchelaar EF, Zhernakova A, et al. A novel biomarker panel for irritable bowel syndrome and the application in the general population. Scientific reports 2016;6:26420.
12. Pike BL, Paden KA, Alcala AN, et al. Immunological biomarkers in postinfectious irritable bowel syndrome. J Travel Med 2015;22:242-50.
13. Ringel Y, Williams RE, Kalilani L, et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:68-72.
14. Seo AY, Kim N, Oh DH. Abdominal bloating: Pathophysiology and treatment. J Neurogastroenterol Motil 2013;19:433-53.
15. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010;25: 1366-73.
16. Hoffmann B, Schwarz M, Mehta A, et al. Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007;5:1447-53.
17. Wim T, Bruce P, Birgitte W, et al. Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrol Dial Transplant 2008;23:294-300.
18. Hamidreza R, Ehsan ZB, Ammar H-K, et al. Anxiety, depression and distress among irritable bowel syndrome and their subtypes: an epidemiological population based study. Adv Biomed Res 2016;5:183.
19. Sadik R, Björnsson E, Simrén M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010; 22.1:102-8.
20. Cristiane KN , Ciro GM, Sônia Letícia SL, Maria AM, et al. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig 2016;108:59-64.
21. Eun-Hyun L , Oran K, Ki BH, et al. Irritable bowel syndrome-specific health-related quality of life instrument: development and psychometric evaluation. Health Qual Life Outcomes 2016;14.1:22.
22. Smith GD. Assessment of health related quality of life (HRQoL) in irritable bowel syndrome. Gastrointest Nurs 2012;10:31-5.
23. American College of Gastroenterology Task Force on IBS, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:1-35.
24. Singh P, Staller K, Barshop K, et al. Patients with irritable bowel syndrome-diarrhea have lower diseasespecific quality of life than irritable bowel syndromeconstipation. World J Gastroenterol 2015;21:8103-9
25. Norio S, Ken S, Ippei T, et al. Irritable bowel syndrome and quality of life in a community-dwelling population in Japan. Int J Psychiatry Med 2018;53:159-70.